Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Sven Mensing"'
Autor:
Diego Valderrama, Ana Victoria Ponce‐Bobadilla, Sven Mensing, Holger Fröhlich, Sven Stodtmann
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 1, Pp 41-53 (2024)
Abstract Recently, the use of machine‐learning (ML) models for pharmacokinetic (PK) modeling has grown significantly. Although most of the current approaches use ML techniques as black boxes, there are only a few that have proposed interpretable ar
Externí odkaz:
https://doaj.org/article/b01c91b33a9843feb724d969b1c2d471
Autor:
Sathej Gopalakrishnan, Rajeev Menon, Ahmed A. Suleiman, Arnon P. Kater, Stephan Stilgenbauer, John F. Seymour, Brenda Chyla, Tong Lu, Su Young Kim, Andrew W. Roberts, Jennifer A. Woyach, Sven Mensing, Ahmed Hamed Salem
Publikováno v:
HemaSphere, Vol 7, Iss 12, p e983 (2023)
Externí odkaz:
https://doaj.org/article/a2f017128b0e46e6a3b38e44b5b505e7
Autor:
John Powderly, Alexander Spira, Shunsuke Kondo, Toshihiko Doi, Jason J. Luke, Drew Rasco, Bo Gao, Minna Tanner, Philippe A. Cassier, Anas Gazzah, Antoine Italiano, Diego Tosi, Daniel E. Afar, Apurvasena Parikh, Benjamin Engelhardt, Stefan Englert, Stacie L. Lambert, Sreeneeranj Kasichayanula, Sven Mensing, Rajeev Menon, Gregory Vosganian, Anthony Tolcher
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 1, Pp 277-287 (2021)
Budigalimab is a humanized, recombinant, Fc mutated IgG1 monoclonal antibody targeting programmed cell death 1 (PD‐1) receptor, currently in phase I clinical trials. The safety, efficacy, pharmacokinetics (PKs), pharmacodynamics (PDs), and budigali
Externí odkaz:
https://doaj.org/article/2e9537a22ea94fefa65b2b3c6cd4e048
Publikováno v:
Clinical and Translational Science, Vol 12, Iss 6, Pp 625-632 (2019)
Venetoclax is an approved drug for the treatment of some hematological malignancies. Venetoclax can cause reduction in B‐lymphocyte counts as an on‐target effect. The purpose of this analysis is to quantify the relationship between venetoclax exp
Externí odkaz:
https://doaj.org/article/44907fa90dd54107b7a9ad254526caea
Autor:
Ana Victoria Ponce-Bobadilla, Sven Stodtmann, Mong-Jen Chen, Insa Winzenborg, Sven Mensing, Jonas Blaes, Tobias Haslberger, Loic Laplanche, Ingeborg Dreher, Nael M. Mostafa
Publikováno v:
Clinical Pharmacokinetics. 62:623-634
Autor:
Mohamed Badawi, Xin Chen, Patrick Marroum, Ahmed A. Suleiman, Sven Mensing, Anette Koenigsdorfer, Julia Teresa Schiele, Tammy Palenski, Divya Samineni, David Hoffman, Rajeev Menon, Ahmed Hamed Salem
Publikováno v:
Clinical Drug Investigation. 42:657-668
Venetoclax is an approved BCL-2 inhibitor, currently under evaluation in different hematological malignancies in adult and pediatric populations. Venetoclax is available as 10, 50, and 100 mg tablets. To provide an alternative to patients who find ta
Autor:
Jingqi Q. X. Gong, Ahmed A. Suleiman, Rajeev Menon, Rong Deng, Sven Mensing, Ahmed Hamed Salem
Publikováno v:
The Journal of Clinical Pharmacology.
Opportunities and Challenges of Disease Progression Modeling in Drug Development – An IQ Perspective
Autor:
Kosalaram Goteti, Nathan Hanan, Mindy Magee, Jessica Wojciechowski, Sven Mensing, Bojan Lalovic, Yaming Hang, Alexander Solms, Indrajeet Singh, Rajendra Singh, Theodore Robert Rieger, Jin Y. Jin
Publikováno v:
Clinical Pharmacology & Therapeutics.
Autor:
Sven Stodtmann, Doerthe Eckert, Rujuta Joshi, Silpa Nuthalapati, Christine K. Ratajczak, Rajeev Menon, Sven Mensing, Hao Xiong
Publikováno v:
The Journal of Clinical Pharmacology. 62:1236-1246
Autor:
Deanna Brackman, Doerthe Eckert, Rajeev Menon, Ahmed Hamed Salem, Jalaja Potluri, B. Douglas Smith, Andrew H. Wei, John Hayslip, Dale Miles, Sven Mensing, Sathej Gopalakrishnan, Jiuhong Zha
Publikováno v:
Hematological Oncology. 40:269-279
This study evaluated venetoclax population pharmacokinetics (popPK) in patients with treatment-naïve acute myeloid leukemia and assessed the relationship between venetoclax exposure and clinical response for venetoclax in combination with either a h